2016 American Society of Clinical Oncology Annual Meeting*

Download All
June 3-7, 2016; Chicago, Illinois
Heather Wakelee, MD, and David Gandara, MD, review data from key lung cancer presentations at the 2016 American Society of Clinical Oncology Annual Meeting.
David R. Gandara, MD
person default
Heather Wakelee, MD
Heather Wakelee, MD

Lung Cancer

Crizotinib shows antitumor activity, with a tolerable safety profile, in NSCLC with MET exon 14 alterations.

Released: June 7, 2016

Evaluation of patients with metastatic NSCLC treated past first RECIST defined progression with anti–PD-1 therapy in clinical trials finds that a small proportion (8%) attained a subsequent response to treatment.

Released: June 6, 2016

Concurrent CRT using modern RT techniques produced similar rates of survival and toxicity whether given once daily or twice daily for limited-stage SCLC.

Released: June 7, 2016

DFS and OS outcomes similar in patients with early-stage, resected NSCLC for 4 different cisplatin-based doublet chemotherapy regimens tested.

Released: June 8, 2016

Early phase data suggest that osimertinib is safe, tolerable, and produces clinical benefit in patients with difficult-to-treat NSCLC.

Released: June 10, 2016

In oligometastatic NSCLC without progression after first-line systemic therapy, local consolidative therapy significantly improved PFS without increasing toxicity.

Released: June 9, 2016

Brigatinib showed a 54% ORR with a median PFS > 1 year in patients with crizotinib-refractory ALK+ NSCLC.

Released: June 13, 2016

J-ALEX met its primary endpoint--alectinib significantly improved PFS vs crizotinib with a favorable safety profile in ALK inhibitor–naive patients with ALK-positive NSCLC.

Released: June 10, 2016

Lorlatinib is well tolerated in ALK+ and ROS1+ NSCLC and shows antitumor activity, including intracranial activity, in patients pretreated with available inhibitors of ALK and ROS1.

Released: June 7, 2016

Treatment-experienced patients with rare RET-fusion driver mutations responded well to single-agent vandetanib in this small trial, with more than one half of patients achieving an objective response.

Released: June 6, 2016

Here are the studies being presented at ASCO 2016 that David R. Gandara, MD, and I think are most likely to affect clinical practice in our patients with lung cancer.

David R. Gandara, MD person default Heather Wakelee, MD Released: May 31, 2016

David R. Gandara, MD, and Heather A. Wakelee, MD, review and analyze important lung cancer presentations from the 2016 clinical oncology meeting in Chicago.

David R. Gandara, MD Heather Wakelee, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: August 18, 2016 Expired: No longer available for credit

In this phase I study, the antibody–drug conjugate rovalpituzumab tesirine demonstrated good response rates in patients with relapsed/refractory SCLC and high DLL3 expression, making it the first biomarker-directed therapy with activity in this disease.

Released: June 7, 2016

In this downloadable slideset, David R. Gandara, MD, and Heather A. Wakelee, MD, review important lung cancer presentations from the 2016 clinical oncology meeting in Chicago.

Released: August 17, 2016
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC in collaboration with Postgraduate Institute for Medicine
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue